Abstracts Archive - Page 386 of 2607 - ACR Meeting Abstracts

Abstract Number: 1311 • ACR Convergence 2023
T Cell Subset Signatures Predicted Clinical Response to Etanercept-biosimilar Yisaipu in Patients with Rheumatoid Arthritis
Huaqun Zhu¹, Sumei Tang¹, Gong Cheng¹, Yingni Li¹, Yun Li¹, Feng Sun¹, Xiaolin Sun¹, Jiahui Cheng¹, Ru Li¹ and Zhanguo Li², ¹Peking University People’s Hospital, Beijing, China, ²Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China
Background/Purpose: Our study aimed to use machine-learning approaches to characterize the immune cell profiles of patients who were inadequate responders to Etanercept-Biosimilar Yisaipu (Yisaipu-IRs) and…
Abstract Number: 1325 • ACR Convergence 2023
Integrated Safety Analysis of Filgotinib in Patients with Moderate to Severe Active Rheumatoid Arthritis with a Maximum Exposure of 8.3 Years
Kevin Withrop¹, Daniel Aletaha², Roberto F. Caporali³, Yoshiya Tanaka⁴, Tsutomu Takeuchi⁵, Paul Van Hoek⁶, Pieter-Jan Stiers⁷, Vijay Rajendran⁸, Katrien Van Beneden⁶, Jacques-Eric Gottenberg⁹ and Gerd Burmester¹⁰, ¹Oregon Health & Science University, Schools of Medicine and Public Health,, Portland, OR, ²Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria, ³Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, ⁴University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁶Medical Safety, Galapagos NV, Mechelen, Belgium, ⁷Biostatistics, Galapagos NV, Mechelen, Belgium, ⁸Clinical Research, Galapagos NV, Mechelen, Belgium, ⁹Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, ¹⁰Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany
Background/Purpose: Filgotinib (FIL) is an oral Janus kinase 1 preferential inhibitor, approved for the treatment of moderate to severe active rheumatoid arthritis (RA). In previous…
Abstract Number: 1350 • ACR Convergence 2023
Identification of ACR Guidelines for SLE Pregnancy Care in the Electronic Health Record
Noah Forrest¹, Joshua Waytz², April Barnado³, Megan Clowse⁴, Theresa Walunas¹ and Rosalind Ramsey-Goldman⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern Medicine, Chicago, IL, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Duke University, Chapel Hill, NC, ⁵Northwestern University, Chicago, IL
Background/Purpose: SLE is an autoimmune disease with an increased risk for poor outcomes in pregnancy. In 2020, ACR specified several recommendations to assist clinicians in…
Abstract Number: 1353 • ACR Convergence 2023
Sexual Dysfunction in Women with Systemic Lupus Erythematosus: A Cross-Sectional Multicentre Study
Maria Helena Lourenco¹, Rita Torres², Santiago Rodrigues-Manica³, Vanessa Fraga⁴, Ana Catarina Abreu⁵, Roberto Costa⁶, Carolina Ochôa Matos⁷, Beatriz Mendes⁸, Beatriz Samões⁹, Inês Silva¹, Fernando Pimentel-Santos¹⁰, Manuela Costa¹, Jaime Branco¹¹ and Alexandre Sepriano¹², ¹Hospital Egas Moniz, Lisbon, Portugal, ²Hospital Egas Moniz, Lisboa, Portugal, ³Hospital Egas Moniz, CHLO, Lisboa, Portugal, ⁴Hospital Garcia de Orta, Nogueira da Regedoura, Portugal, ⁵Hospital Garcia de Orta, Lisboa, Portugal, ⁶Centro Hospitalar Lisboa Norte, Lisboa, Portugal, ⁷Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ⁸Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ⁹Centro Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia, Portugal, ¹⁰NOVA Medical School; Universidade NOVA e Lisboa, Lisboa, Portugal, ¹¹CHLO, EPE - Hospital Egas Moniz, Lisbon, Portugal, ¹²Leiden University Medical Centre, Portela Loures, Portugal
Background/Purpose: Due to its multisystemic involvement, systemic lupus erythematosus (SLE) can have a significant impact on patients' quality of life (QoL). Sexual (dis)function is a…
Abstract Number: 1354 • ACR Convergence 2023
The Impact of Pregnancy Intention on Depression and Quality of Life in Women with Lupus
Ceshae Harding¹, Amanda Eudy², Catherine Sims¹, Cuoghi Edens³, Mehret Birru Talabi⁴, Rosalind Ramsey-Goldman⁵, Laura Neil¹ and Megan Clowse⁶, ¹Duke University, Durham, NC, ²Duke University, Raleigh, NC, ³University of Chicago, Chicago, IL, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Northwestern University, Chicago, IL, ⁶Duke University, Chapel Hill, NC
Background/Purpose: Mental health conditions are the leading cause of maternal mortality across most of the United States. Among individuals with SLE, pregnancy intention has been…
Abstract Number: 1336 • ACR Convergence 2023
Adalimumab and Etanercept Serum Levels in Rheumatoid Arthritis Patients with and Without a Disease Flare During Tapering
Zohra Layegh¹, Femke Hooijberg², Floris loeff³, lisanne Dijk³, Gaelle vaz³, Theo Rispens³, radboud J.e.m. Dolhain⁴, Gertjan Wolbink⁵ and Pascal de Jong¹, ¹Erasmus medical center, Rotterdam, Netherlands, ²Amsterdam Rheumatology and Immunology Center, Location Reade, Department of Rheumatology, Dr. Jan van Breemenstraat 2, 1056 AB, Amsterdam, Netherlands, ³Sanquin Diagnostic Service, Biologics Laboratory, Amsterdam, Netherlands, ⁴Rheumatology, Erasmus MC, Rotterdam, Netherlands, ⁵Reade, Amsterdam, Netherlands
Background/Purpose: Due to the improved management strategies and availability of biologic disease-modifying antirheumatic drugs (bDMARDs), ~60% of the rheumatoid arthritis (RA) patients will achieve sustained…
Abstract Number: 1347 • ACR Convergence 2023
Continuing Biologic DMARDs During Pregnancy in Women with Rheumatic Disease Was Not Associated with Increased Unfavorable Pregnancy Outcomes, Serious Infections, and Adverse Effects of Vaccination
Hiromi Shimada¹, Risa Wakiya², Shusaku Nakashima², Taichi Miyagi³, Yusuke Ushio⁴, Koichi Sugihara⁵, Rina Mino⁶, Mao Mizusaki², Kanako Chujo⁷, Ryoko Kagawa⁴, Hayamasa Yamaguchi⁴, Tomohiro Kameda² and Hiroaki Dobashi², ¹Kagawa University, Kagawa, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, ⁴Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ⁵Kagawa University, Miki-cho, Kita-gun, Japan, ⁶Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ⁷Kagawa University, Miki, Kita District, Kagawa, Japan
Background/Purpose: It is important to control disease activity during pregnancy in women with rheumatic diseases because its exacerbation is associated with increased adverse pregnancy outcomes.…
Abstract Number: 1358 • ACR Convergence 2023
Experiences and Attitudes Related to Assisted Reproductive Technologies Among Women with Systemic Rheumatic Disease
Sanjana Adurty¹, Lucy Masto², Amaya Smole², Caroline Siegel², Sarah Lieber³, Jonah Levine², Bessie Stamm², Lisa Mandl³, Michael Lockshin³, Medha Barbhaiya³ and Lisa Sammaritano³, ¹Weill Cornell Medical College, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Systemic rheumatic disease (SRD) may be associated with decreased fertility. Advances in the safety and efficacy of oocyte cryopreservation (OOC) and other assisted reproductive…
Abstract Number: 1348 • ACR Convergence 2023
Reproductive Outcomes for Women with Vasculitis
Catherine Sims¹, Christine Yeung², Heather Tam³, Joyce Kullman⁴, Amanda Eudy⁵, Renee Borchin⁶, Cristina Burroughs⁶, Megan Clowse⁷ and Peter Merkel², ¹Duke University School of Medicine, Durham, NC, ²University of Pennsylvania, Philadelphia, PA, ³Vasculitis Patient Powered Research Network, Stanford, CA, ⁴Vasculitis Foundation, Kansas City, MO, ⁵Duke University, Raleigh, NC, ⁶University of South Florida, Tampa, FL, ⁷Duke University, Chapel Hill, NC
Background/Purpose: There are limited data on the reproductive health of women with vasculitis. This study utilized a large, prospective, international vasculitis pregnancy registry to survey…
Abstract Number: 1335 • ACR Convergence 2023
Effectiveness of Longstanding Exercise Therapy versus Usual Care in People with Rheumatoid Arthritis and Severe Functional Limitations: A Randomized Controlled Trial (L-EXTRA)
Max Teuwen¹, Salima van Weely¹, Thea Vliet Vlieland², Manja van Wissen¹, Wilfred Peter¹, Alfons den Broeder³, Dirkjan van Schaardenburg⁴, Wilbert van den Hout¹, Cornelia van den Ende³ and Maaike gademan¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leids University Medical Center, Leiden, Netherlands, ³Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Reade, Amsterdam, Netherlands
Background/Purpose: Supervised exercise therapy is an effective and safe treatment option for people with rheumatoid arthritis (RA). However, most studies involve interventions of relatively short…
Abstract Number: 1340 • ACR Convergence 2023
Recent Trends in Treatment Patterns for Rheumatoid Arthritis in Response to Emerging Data
Stephanie Song¹, Michael George², Ted R Mikuls³, Bryant England⁴, Brian Sauer⁵, Grant Cannon⁶ and Joshua Baker², ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Janus kinase inhibitors (JAKi) have demonstrated substantial efficacy in decreasing symptoms and in reducing progressive joint damage in patients with rheumatoid arthritis (RA). In…
Abstract Number: 1271 • ACR Convergence 2023
Upregulation of IFNγ-Response Genes in Monocytes and T Cells Identified by Single-Cell Transcriptomics in Patients with Anti-CCP Antibody-Positive Rheumatoid Arthritis (RA)
Bong-Ki Hong¹, Sungyong You², Naeun Lee¹, Jung Gon Kim³, Kijun Lee⁴, Ji Hyeon Ju⁵, Wan-Uk Kim¹ and Ho-Youn Kim⁶, ¹The Catholic University of Korea, Seoul, South Korea, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³Inje University Ilsan Paik Hospital, Goyang, South Korea, ⁴YiPSCELL, Secho, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁶HoYoun Kim's Clinic for Arthritis Rheumatism, Seoul, South Korea
Background/Purpose: Recent research has revealed a significant upregulation of IFNγ-related genes in RA patients, though the underlying mechanisms and implications are still unclear. To further…
Abstract Number: 1331 • ACR Convergence 2023
Long-term Effectiveness of a Lifestyle Program for Rheumatoid Arthritis: One-year Follow-up of the “Plants for Joints” Randomized Clinical Trial
Carlijn Wagenaar¹, Wendy Walrabenstein¹, Marike Van der Leeden², Franktien Turkstra², Jos W.R. Twisk¹, Maarten Boers¹, Henriët van Middendorp³, Peter Weijs⁴ and Dirkjan van Schaardenburg⁵, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Reade Rheumatology Center, Amsterdam, Netherlands, ³Leiden University, Leiden, Netherlands, ⁴Amsterdam University of Applied Sciences, Amsterdam, Netherlands, ⁵Reade, Amsterdam, Netherlands
Background/Purpose: The 16-week Plants for Joints (PFJ) multidisciplinary lifestyle program, based on a whole-food plant-based diet, physical activity, and stress management, significantly reduced 28-joint Disease…
Abstract Number: 1289 • ACR Convergence 2023
Increases in Serum Levels of Tartrate-Resistant Acid Phosphatase 5b Reflected Radiographic Progression of Joint Damage in Treated Rheumatoid Arthritis
Takayoshi Owada¹, Takayuki Kobayashi¹, Ayae Tanaka², Kei Ikeda², Hirokuni Hirata¹, Masafumi Arima³, Kazuhiro Kurasawa² and Yasutsugu Fukushima¹, ¹Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan, ²Dokkyo Medical University, Mibu-machi, Shimotsuga-gun, Japan, ³Dokkyo Medical University, Koshigaya, Japan
Background/Purpose: Rheumatoid Arthritis (RA) is one of inflammatory arthritis, and this autoimmune-mediated polyarthritis results in structural joint destruction. Articular bone erosion leading to joint destruction in RA…
Abstract Number: 1150 • ACR Convergence 2023
A Comparative Study of Cryofibrinogenemia Before and After COVID-19 Era
Carmen Lasa¹, Maria Enriqueta Peiró², Juan Irure-Ventura², Amparo Sánchez², Adrian Martin-Gutierrez², carmen secada², monica renuncio garcia², Marcos Lopez-Hoyos³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, IDIVAL., La Cavada, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Cryofibrinogenemia (CF) is an under-recognized syndrome due to the lack of definitive criteria and the rarity of disease. CF may be primary (essential) or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].